Get the Stockscreener App
2.6407
3.97%
-0.1093
OncoCyte Corporation stock is traded at $2.6407, with a volume of 578.
It is down -3.97% in the last 24 hours and down -15.36% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$2.75
Open:
$2.8
24h Volume:
578
Relative Volume:
0.02
Market Cap:
$43.77M
Revenue:
$709.00K
Net Income/Loss:
$-43.14M
P/E Ratio:
-0.2571
EPS:
-10.27
Net Cash Flow:
$-20.35M
1W Performance:
-5.69%
1M Performance:
-15.36%
6M Performance:
-6.36%
1Y Performance:
-33.82%
1-Day Range:
$2.80
$2.80
1-Week Range:
$2.50
$2.80
52-Week Range:
$2.285
$4.305
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
Compare OCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| OCX | 2.80 | 43.77M | 709.00K | -43.14M | -20.35M | -10.27 |
| VRTX | 448.10 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.65 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.86 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
Seasoned Financial executive joins Oncocyte as CFO - Reuters
PURA VIDA INVESTMENTS, LLC Expands Stake in OncoCyte Corp - GuruFocus.com
OncoCyte stock maintains Buy rating with Needham after GraftAssure RUO launch - Investing.com
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript - Insider Monkey
OncoCyte: Q3 Earnings Snapshot - Darien Times
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress i - GuruFocus.com
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... - Yahoo Finance
OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates - TipRanks
OncoCyte Corp (OCX) Q3 2024 Earnings: EPS of -$0.98 Misses Estimates, Revenue Falls Short at $115,000 - GuruFocus.com
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - The Manila Times
Oncocyte Corporation (OCX) Quarterly 10-Q Report - Quartz
What to Expect from OncoCyte's Earnings - Benzinga
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - ForexTV.com
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times
Oncocyte Corp expands equity incentive plan - Investing.com India
Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia
OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria
OncoCyte shares maintain Buy rating from Needham - Investing.com
OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance
Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia
Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa
Oncocyte CFO acquires $99,999 worth of company shares - Investing.com
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com
OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance
OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
LENSAR reports inducement grants - Medical Buyer
Oncocyte Corporation enters into securities purchase agreement - Medical Buyer
Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com
Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):